7 research outputs found
Treating Woman with Myo-Inositol Vaginal Suppositories Improves Partner’s Sperm Motility and Fertility
Motility is the feature that allows spermatozoa to actively reach and penetrate the female gamete during fertilization. When this function is altered, and especially decreased, troubles in conceiving may occur. In this study, we demonstrated that treating fertile women with myo-inositol (MI) vaginal suppositories ameliorated their partners’ sperm motility and also positively affected their conceiving capacity, without changes in cervical mucus structural and biochemical characteristics. Indeed, by means of the postcoital test on female cervical mucus, a significant improvement especially in progressive sperm motility was recorded after MI suppository use. Concomitantly, after MI treatment, a reduction of immotile spermatozoa percentage was observed. Importantly, MI vaginal supplementation positively correlated with a pregnancy for 5 of the 50 couples enrolled in the study, leading us to speculate that this substance may substantially contribute to create in the cervical mucus an ideal milieu that makes spermatozoa more motile and functionally able to fertilize. Even though the detailed mechanism is still unclear, these results should encourage MI vaginal use for the clinical improvement of male infertility, through their partners
Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study
Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization
n/
Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study
Abstract Background Aim of this pilot study is to examine the effects of myo-inositol administration on ovarian response and oocytes and embryos quality in non PolyCystic Ovary Syndrome (PCOS) patients undergoing multiple follicular stimulation and in vitro insemination by conventional in vitro fertilization or by intracytoplasmic sperm injection. Methods One hundred non-PCOS women aged Results Total length of the stimulation was similar between the two groups. Nevertheless, total amount of gonadotropins used to reach follicular maturation was found significantly lower in group B. In addition, the number of oocytes retrieved was significantly reduced in the group pretreated with myo-inositol. Clinical pregnancy and implantation rate were not significantly different in the two groups. Conclusions Our findings suggest that the addition of myo-inositol to folic acid in non PCOS-patients undergoing multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of rFSH whilst maintaining clinical pregnancy rate. Further, a trend in favor of increased incidence of implantation in the group pretreated with myo-inositol was apparent in this study. Further investigations are warranted to clarify this pharmacological approach, and the benefit it may hold for patients.</p
Pretreatment with myo-inositol in non policystic ovary syndroe patients undergoing multiple follicular stimulation for IVF: a pilot study
Background: Aim of this pilot study is to examine the effects of myo-inositol administration on ovarian response
and oocytes and embryos quality in non PolyCystic Ovary Syndrome (PCOS) patients undergoing multiple follicular
stimulation and in vitro insemination by conventional in vitro fertilization or by intracytoplasmic sperm injection.
Methods: One hundred non-PCOS women aged <40 years and with basal FSH <10 mUI/ml were down-regulated
with triptorelin acetate from the mid-luteal phase for 2 weeks, before starting the stimulation protocol for oocytes
recovery. All patients received rFSH, at a starting dose of 150 IU for 6 days. The dose was subsequently adjusted
according to individual response. Group B (n = 50) received myo-inositol and folic acid for 3 months before the
stimulation period and then during the stimulation itself. Group A (n-50) received only folic acid as additional
treatment in the 3 months before and through treatment.
Results: Total length of the stimulation was similar between the two groups. Nevertheless, total amount of
gonadotropins used to reach follicular maturation was found significantly lower in group B. In addition, the number
of oocytes retrieved was significantly reduced in the group pretreated with myo-inositol. Clinical pregnancy and
implantation rate were not significantly different in the two groups.
Conclusions: Our findings suggest that the addition of myo-inositol to folic acid in non PCOS-patients undergoing
multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of
rFSH whilst maintaining clinical pregnancy rate. Further, a trend in favor of increased incidence of implantation in
the group pretreated with myo-inositol was apparent in this study. Further investigations are warranted to clarify
this pharmacological approach, and the benefit it may hold for patients